Abstract. It is well-known that monocytes are a heterogeneous cell population and different monocyte subsets play important roles in rheumatoid arthritis (RA). Cluster of differentiation (CD)64 is one of Fc receptor, which initiates immunological and inflammatory reactions. However, the roles in RA remain to be elucidated. In the present study, the expression of CD64, CD40, CD163, CD206, HLA-DR, CD80 and CD86 on monocytes and the expression of CD64 on monocyte subsets were determined by flow cytometry. The expression of CD64 on monocyte subsets in patients with RA was further analyzed for their correlation with markers of autoimmune response, inflammation, disease activity of RA and serum cytokines. Compared to the health volunteers, the expression of CD64 on monocytes and each monocyte subset were significantly elevated in RA patients.
Introduction
Rheumatoid arthritis (RA) is a chronic inflammatory disease which causes pain and dysfunction and leads to the destruction of joints. Activation and recruitment of immune cells, especially lymphocytes and monocytes into the joints, are major characters of RA (1, 2) . The mechanisms underlying RA are complex, including genetic and environmental factors, as well as abnormalities of both innate immunity and adaptive immunity (3) . Although the etiopathology of RA is not fully understood, it is known that monocytes/macrophages, neutrophils, T cells and B cells are involved in the mechanisms that drive the onset of RA (4) . These cells play a key role in the progression of RA through the production of proinflammatory cytokines, leading to the development of an inflammatory environment and immune cell recruitment in the joints.
In humans, monocytes are a heterogeneous cell population composed of three distinct subsets based on their expression of CD14 and CD16 (5 (6) . The two CD14 ++ subsets are thus recognized to expand in various inflammatory diseases and are suggested to play a significant role in disease processes (7, 8) . Recent reports have shown that the proportion of monocyte subsets was aberrant in RA patients (9, 10) . CD64 (FcgRI), a Fc receptor for IgG, is constitutively expressed on macrophages and monocytes. CD64 is the high-affinity receptor for monomeric IgG or Ig in immune complexes that can initiates immunological and inflammatory reactions on immune competent cells, including monocytes and joint-stationed macrophages (11) (12) (13) In the present study, we detected the expression of CD64 on monocyte subsets in patients with RA and HV. The correlation between the expression of CD64 on monocyte subsets and the activity of RA was also investigated. Moreover, the cytokines secretion of CD64 + monocyte subsets in patients with RA was measured.
Patients and methods

Subjects.
A total of 46 patients fulfilled the revised American College of Rheumatology criteria for RA (19) were recruited from the First Affiliated Hospital of Nanchang University. Among them, 5 patients were new-onset RA (<6 months disease duration) (20) . All patients were administered disease-modifying anti-rheumatic drugs (DMARDs), including glucocorticoid and immunosuppressor therapy. Disease activity of RA was calculated using the disease activity score 28 (DAS28) (21) . The patient characteristics of this group are shown in Table I . In addition, the present study included 22 HV (female 81.8%, mean age 51.2±11.6 years) who were unrelated to the patients and did not have inflammatory or autoimmune diseases. The study was approved by the Ethics Committee of the First Affiliated Hospital of Nanchang University (019) and was carried out in compliance with the Helsinki Declaration. Written informed consent was obtained from all participants before they entered the present study.
Flow cytometry analysis.
Peripheral blood mononuclear cells (PBMCs) were isolated from the fresh peripheral blood of RA patients and HV on Ficoll-Paque gradient (Sigma-Aldrich; Merck KGaA, Darmstadt, Germany). The membrane molecules of monocytes were analyzed immediately using flow cytometry. The following antibodies were used: ECD-conjugated anti-CD14, PC5-conjugated anti-CD16 (BD Biosciences, San Diego CA, USA), PE-conjugated anti-CD163, anti-CD206, and anti-CD86, FITC-conjugated anti-CD80, anti-CD40, anti-CD64, anti-HLA-DR (MIH clones; eBioscience; Thermo Fisher Scientific, Inc., Waltham, MA, USA). Monocyte subsets identified as detailed above based on their expression of CD14 and CD16 (5) . Briefly, 5x10 5 PBMCs was incubated simultaneously with 10 µl of ECD-conjugated anti-CD14, 10 µl of PC5-conjugated anti-CD16, and PE-conjugated anti-CD64 on ice in the dark for 30 min. Cells incubated with PE-conjugated mouse IgG were used as isotype controls. Expression of CD64 was analyzed on each monocyte subset using a CYTOMICS FC 500 flow cytometer (Beckman Coulter, Inc., Brea, CA, USA) and data analyzed with the associated software programs (CXP). Erythrocyte sedimentation rate (ESR) blood routine measurement. ESR and blood routine were determined according to the instructions described by the manufacturer.
Autoantibody measurement. Level of rheumatoid factor (RF) was determined using nephelometry methods according to the instructions described by the manufacturer (IMMUNE800; Beckman Coulter, Inc.). Anti-citrullinated protein antibodies (ACPA) from serum IgG were measured using commercially ELISA kits (Kexin, Shanghai, China). frequency of CD64-expressing CD14 ++ CD16 -monocytes and CD64-expressing CD14 ++ CD16 + monocytes were significantly elevated compared to CD64-expressing CD14 + CD16 ++ monocytes in both HV (P<0.0001; Fig. 3D ) and RA patients (P<0.0001; Fig. 3F ). And, the frequency of CD64-expressing CD14 ++ CD16 -monocytes was significantly elevated compared to CD64-expressing CD14 ++ CD16 + monocytes in RA patients (P<0.0001; Fig. 3F ), but no differences was found in HV (P= 0.1389; Fig. 3D ). As showed in Fig. 3E Fig. 4A ; r= 0.4484, P= 0.0061, Fig. 4B ), the expression of CD64 on CD14 ++ CD16 + monocytes positively correlated with ESR and CRP in RA patients (r0.5128, P= 0.0006, Fig. 4C ; r= 0.4721, P= 0.0036, Fig. 4D ), the expression of CD64 on CD14 + CD16 ++ monocytes positively correlated with ESR (r= 0.3336, P= 0.0330, Fig. 4E ), whereas the expression of CD64 on CD14 + CD16 ++ monocytes did not correlate with CRP (r= 0.1356, P= 0.4297, Fig. 4F ). However, no obvious relationship was found between the expression of CD64 on CD14 ++ CD16 -monocytes, CD14 + CD16 ++ monocytes, CD14 ++ CD16 + monocytes and WBC, neutrophil count, the percent of neutrophil, IgG, C3, C4 (data no show).
Expression of CD64 on monocyte subsets correlates with markers of autoimmune response. The hallmark antibodies of RA, such as RF and ACPA, were determined and analyzed for their correlation with the expression of CD64 on monocyte subsets. As shown in Fig. 5 , the expression of CD64 on CD14 ++ CD16 -monocytes and CD14 ++ CD16 + monocytes were significantly increased in patients with positive ACPA and RF respectively (P=0.0460, Fig. 5A ; P= 0.0035, Fig. 5B ; P= 0.0416, Fig. 5C ; P= 0.0042, Fig. 5D ). However, no obvious relationship was found between the expression of CD64 on CD14 + CD16 ++ monocytes and ACPA, RF (P=0.6718, Fig. 5E; P=0.8128, Fig. 5F ).
Expression of CD64 on monocyte subsets correlates with disease activity of RA. Aforementioned data indicated that the expression of CD64 on monocyte subsets was correlated with markers of inflammation and autoimmune response. Thus, the correlation between the expression of CD64 on monocyte subsets and disease activity were investigated. Data showed that both the expression of CD64 on CD14 ++ CD16 -monocytes and CD14 ++ CD16 + monocytes were positively correlated with DAS28 score (r=0.3506, P=0.0212; r=0.3208, P= 0.0360) (Fig. 6A and B) , while the expression of CD64 on CD14 + CD16 ++ monocytes did not correlate with DAS28 score (r=0.2587, P=0.0938; Fig. 6C ).
Subsequently, we compared the CD64 expression on monocyte subsets between patients with new-onset and re-visiting RA. Data showed that the expression of CD64 on monocytes subsets tends to be elevated in patients with new-onset RA, but a significant difference was not reached (P>0.0500; Fig. 6D) .
Association between the expression of CD64 on monocyte subsets and serum cytokine concentration. Among the three serum inflammatory cytokines, levels of IL-6 and IL-8 were significantly higher in patients with RA than in HV (P= 0.0011, Fig. 7A ; P= 0.0387, Fig. 7B ), no significant difference was observed in the levels of IL-10 between patients with RA and HV (P= 0.8994; Fig. 7C ). To determine whether increased levels of CD64 on monocyte subsets play a role in the secretion of serum cytokines (IL-6 and IL-8), RA patients were divided into two groups according to their CD64 levels (average of MFI) on monocytes subsets: RA high Fig. 7D ). And, no significant difference was observed in the levels of IL-8 between RA patients with high levels of CD64 on each monocyte subset and low levels of CD64 on each monocyte subset (P>0.05; Fig. 7E ). These results indicate that increased levels of CD64 on CD14 ++ CD16 + monocytes in RA patients are associated with increased secretion of IL-6. ). The three subsets of monocytes perform different functions. The classical subset is rapidly recruited to the sites of inflammation and appears to act as phagocytic scavenger cells and regulators of inflammation (22, 23) . The intermediate monocytes play a proinflammatory role, being increased in blood from patients with acute inflammation (24, 25) . The nonclassical monocytes are often referred to as patrolling monocytes (26) . Previous researchs have reported monocytes play a important role in the progression of RA. The onset and severity of RA might also be due to the seasonality of monocyte subsets was aberrant.
Discussion
Although an increase in CD14 ++ CD16 + monocytes and an decreased in CD14 ++ CD16 -monocytes in patients with RA have been reported, the increase in CD14 + CD16 ++ monocytes remained controversial (27, 28) . In consistent with the report of Patricia Lacerte (28) , this study demonstrate that circulating with RA. The reasons for these outcomes are probably due to differences in the disease duration and ongoing treatments. An assessment of the expression of the characteristic phenotypic markers CD40, CD64, CD163, CD206, HLA-DR, CD80 and CD86 helped to characterize further the monocyte response in patients with RA. In consistent with the results of other researches (16, 29) , we found that the expression of CD64 on monocytes was significantly elevated in RA patients compared to HV, no changes of other markers between patients with RA and HV. The increased expression of CD64 on monocytes in patients with active RA may suggest the progression of the disease (16) , and may also reflect the activation of the monocytes. Although an increase in CD64 on monocytes subsets in patients with RA has been reported (30) , the possibility of correlation between the expression of CD64 on each monocytes subset and disease activity in patients with RA has not yet been investigated. Our results support previous observations (30) Little is known about the possibility of correlation between the expression of CD64 on each monocyte subset and the proportion of each monocyte subset in patients with RA. We found that the proportion of CD14 ++ CD16 + monocytes positively correlated with the expression of CD64 on CD14 ++ CD16 + monocytes in RA patients, whereas the proportion of CD14 ++ CD16 -monocytes negatively correlated with the expression of CD64 on CD14 ++ CD16 -monocytes. The reasons for the results are probably due to the facts that the proportion of intermediate monocytes positively correlated with the disease activity of RA, whereas the proportion of classical monocytes negatively correlated (27) and our results showed that the expression of CD64 on CD14 ++ CD16 -monocytes and CD14 ++ CD16 + monocytes were positively correlated with DAS28 score.
It is well-known that RA is a autoimmune disease characterized by the production of autoantibodies including RF, ACPA and autoimmune response is a kind of chronic inflammation against self antigens. In this study, the inflammatory markers, DAS28, the hallmark antibodies of RA including RF and ACPA were first determined and analyzed for their relation with the expression of CD64 on monocyte subsets. Our results showed that the expression of CD64 on (22) (23) (24) (25) (26) ; (2) CD64 is a high-affinity activating receptor that can bind IgG and CRP and stimulate inflammatory processes (16, 31, 32) .
In consistent with previous study (27) , we showed here that levels of IL-6 and IL-8 at baseline were significantly higher in patients with RA than in HV. In addition, we observed that RA patients with high levels of CD64 on CD14 ++ CD16 + monocytes exhibited significantly higher levels of IL-6 compared with the RA patients with low levels of CD64 on CD14 ++ CD16 + monocytes. These results suggested that the levels of CD64 on CD14 ++ CD16 + monocytes is indeed linked to the secretion high concentrations of proinflammatory cytokines.
However, there are some limitations in the present study. First is the relatively small sample size, especially the sample of new-onset RA; these data may be confirmed in large-scale studies. Second, we did not show that each monocyte subset are directly associated with inflammatory cytokines in RA in vitro. Third, No function study and experiments about the mechanism of CD64 have been done in this study. The molecular mechanisms underlying CD64 functions in RA still require further investigation.
In conclusions, results presented in this study demonstrate that blood monocyte subsets isolated from patients with RA have high levels of CD64 and the levels of CD64 on CD14 ++ CD16 -and CD14 ++ CD16 + monocytes correlates with the disease activity of RA. In addition, the levels of CD64 on CD14 ++ CD16 + monocytes is linked to the high secretion level of proinflammatory cytokines. disease activity and severity, performed statistical analyses, and drafted the manuscript. YG carried out the experiments on the expression of cytokines and drafted the manuscript. ZKH and JML conceived of the study, participated in its design and coordination, and helped to draft the manuscript. All authors read and approved the final manuscript.
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